bioMérieux (BIM) Stock Overview
Develops, manufactures, and markets in vitro diagnostic solutions for infectious diseases in France, Europe, Africa, the Middle East, North and South America, the Asia Pacific, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 3/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
BIM Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
bioMérieux S.A. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €108.30 |
| 52 Week High | €128.30 |
| 52 Week Low | €95.90 |
| Beta | 0.65 |
| 1 Month Change | -5.66% |
| 3 Month Change | -14.18% |
| 1 Year Change | 5.15% |
| 3 Year Change | 7.17% |
| 5 Year Change | -12.24% |
| Change since IPO | 983.00% |
Recent News & Updates
Is bioMérieux (EPA:BIM) A Risky Investment?
Nov 10
What You Can Learn From bioMérieux S.A.'s (EPA:BIM) P/E
Oct 05bioMérieux's (EPA:BIM) Conservative Accounting Might Explain Soft Earnings
Sep 12Recent updates
Is bioMérieux (EPA:BIM) A Risky Investment?
Nov 10What You Can Learn From bioMérieux S.A.'s (EPA:BIM) P/E
Oct 05bioMérieux's (EPA:BIM) Conservative Accounting Might Explain Soft Earnings
Sep 12Is bioMérieux S.A. (EPA:BIM) Worth €118 Based On Its Intrinsic Value?
Sep 06Returns At bioMérieux (EPA:BIM) Appear To Be Weighed Down
Jun 20bioMérieux S.A.'s (EPA:BIM) Share Price Matching Investor Opinion
May 28These 4 Measures Indicate That bioMérieux (EPA:BIM) Is Using Debt Reasonably Well
May 07bioMérieux S.A. (EPA:BIM) Not Lagging Market On Growth Or Pricing
Feb 11
FDA Approvals And Expansion Of Installed Base Will Drive Future Success
bioMérieux's strategic plan targets high growth in organic sales and EBIT, with improvements in revenue and net margins by enhancing operational efficiencies.A Look At The Intrinsic Value Of bioMérieux S.A. (EPA:BIM)
Jan 21Slowing Rates Of Return At bioMérieux (EPA:BIM) Leave Little Room For Excitement
Dec 10Shareholder Returns
| BIM | FR Medical Equipment | FR Market | |
|---|---|---|---|
| 7D | -0.9% | -0.4% | 1.2% |
| 1Y | 5.1% | 35.4% | 12.2% |
Return vs Industry: BIM underperformed the French Medical Equipment industry which returned 31.4% over the past year.
Return vs Market: BIM underperformed the French Market which returned 7.7% over the past year.
Price Volatility
| BIM volatility | |
|---|---|
| BIM Average Weekly Movement | 3.2% |
| Medical Equipment Industry Average Movement | 7.3% |
| Market Average Movement | 4.5% |
| 10% most volatile stocks in FR Market | 10.1% |
| 10% least volatile stocks in FR Market | 2.3% |
Stable Share Price: BIM has not had significant price volatility in the past 3 months compared to the French market.
Volatility Over Time: BIM's weekly volatility (3%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1963 | 14,451 | Pierre Boulud | www.biomerieux.com |
bioMérieux S.A. develops, manufactures, and markets in vitro diagnostic solutions for infectious diseases in France, Europe, Africa, the Middle East, North and South America, the Asia Pacific, and internationally. It operates through Clinical Applications and Industrial Applications segments. The company offers CHROMID RANGE, a chromogen culture media; air, surface, and water monitoring systems; BACT/ALERT VIRTUO, a blood sample culture system; BIOFIRE, a multiplex polymerase chain reaction system (PCR); BIOFIRE SPOTFIRE, a lowplex PCR point-of-care system; VITEK MS, a mass spectrometry system; VITEK 2, an automated identification and antimicrobial susceptibility testing (AST) system; API RANGE standardized ID strips; VITEK REVEAL, a rapid AST system; ETEST, a gradient method on culture media; BIOMERIEUX EPISEQ CS, a whole genome sequencing solution for epidemiologic monitoring; VIDAS, a specific marker of severe bacterial infections/sepsis; and Biomérieux vision suite, a software that provides information to support diagnosis and clinical decision making.
bioMérieux S.A. Fundamentals Summary
| BIM fundamental statistics | |
|---|---|
| Market cap | €12.57b |
| Earnings (TTM) | €377.90m |
| Revenue (TTM) | €4.12b |
Is BIM overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| BIM income statement (TTM) | |
|---|---|
| Revenue | €4.12b |
| Cost of Revenue | €1.80b |
| Gross Profit | €2.32b |
| Other Expenses | €1.94b |
| Earnings | €377.90m |
Last Reported Earnings
Jun 30, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | 3.20 |
| Gross Margin | 56.27% |
| Net Profit Margin | 9.17% |
| Debt/Equity Ratio | 9.0% |
How did BIM perform over the long term?
See historical performance and comparisonDividends
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/11/11 09:30 |
| End of Day Share Price | 2025/11/11 00:00 |
| Earnings | 2025/06/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
bioMérieux S.A. is covered by 33 analysts. 13 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Charles Pitman | Barclays |
| Gaurav Jain | Barclays |
| Thomas Jones | Berenberg |